OraSure Technologies
Market Cap
US$485.2m
Last Updated
2019/11/22 23:45 UTC
Data Sources
Company Financials +
Executive Summary
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally.
Snowflake
Fundamentals
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has OraSure Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OSUR has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.1%
OSUR
0.9%
US Medical Equipment
-0.2%
US Market
1 Year Return
-40.9%
OSUR
23.0%
US Medical Equipment
16.1%
US Market
Return vs Industry: OSUR underperformed the US Medical Equipment industry which returned 23% over the past year.
Return vs Market: OSUR underperformed the US Market which returned 16.1% over the past year.
Shareholder returns
| OSUR | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.1% | 0.9% | -0.2% |
| 30 Day | -6.6% | 5.4% | 3.7% |
| 90 Day | 15.1% | 4.7% | 8.5% |
| 1 Year | -40.9%-40.9% | 24.1%23.0% | 18.7%16.1% |
| 3 Year | -12.3%-12.3% | 88.0%82.4% | 46.9%37.4% |
| 5 Year | -13.1%-13.1% | 115.7%92.4% | 61.8%44.0% |
Price Volatility Vs. Market
How volatile is OraSure Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
OraSure Technologies, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year2 weeks ago | Simply Wall St
What Does OraSure Technologies, Inc.'s (NASDAQ:OSUR) Share Price Indicate?1 month ago | Simply Wall St
Read This Before Judging OraSure Technologies, Inc.'s (NASDAQ:OSUR) ROEValuation
Is OraSure Technologies undervalued compared to its fair value and its price relative to the market?
19.66x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: OSUR ($7.83) is trading above our estimate of fair value ($5.21)
Significantly Below Fair Value: OSUR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OSUR is good value based on its PE Ratio (19.7x) compared to the Medical Equipment industry average (45.2x).
PE vs Market: OSUR is poor value based on its PE Ratio (19.7x) compared to the US market (18x).
Price to Earnings Growth Ratio
PEG Ratio: OSUR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: OSUR is good value based on its PB Ratio (1.6x) compared to the US Medical Equipment industry average (3.8x).
Next Steps
Future Growth
How is OraSure Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
-18.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OSUR's earnings are forecast to decline over the next 3 years (-18.9% per year).
Earnings vs Market: OSUR's earnings are forecast to decline over the next 3 years (-18.9% per year).
High Growth Earnings: OSUR's earnings are forecast to decline over the next 3 years.
Revenue vs Market: OSUR's revenue (6.8% per year) is forecast to grow slower than the US market (7.3% per year).
High Growth Revenue: OSUR's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OSUR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has OraSure Technologies performed over the past 5 years?
31.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OSUR has large one-off items impacting its financial results.
Growing Profit Margin: OSUR's current net profit margins (15.6%) are higher than last year (9.9%).
Past Earnings Growth Analysis
Earnings Trend: OSUR's earnings have grown significantly by 31.2% per year over the past 5 years.
Accelerating Growth: OSUR's earnings growth over the past year (40.8%) exceeds its 5-year average (31.2% per year).
Earnings vs Industry: OSUR earnings growth over the past year (40.8%) exceeded the Medical Equipment industry 28.3%.
Return on Equity
High ROE: OSUR's Return on Equity (8.1%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is OraSure Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: OSUR's short term assets ($223.3M) exceeds its short term liabilities ($28.9M)
Long Term Liabilities: OSUR's short term assets ($223.3M) exceeds its long term liabilities (8.9M)
Debt to Equity History and Analysis
Debt Level: OSUR is debt free.
Reducing Debt: OSUR has not had any debt for past 5 years.
Debt Coverage: OSUR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: OSUR has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: OSUR has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if OSUR's debt is covered by short term assets.
Next Steps
Dividend
What is OraSure Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate OSUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OSUR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OSUR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OSUR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OSUR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of OraSure Technologies's salary, the management and board of directors tenure and is there insider trading?
2.3yrs
Average management tenure
CEO
Steve Tang (58yo)
1.6yrs
Tenure
US$2,099,594
Compensation
Dr. Stephen S. Tang, also known as Steve, Ph.D. has been President and Chief Executive Officer at OraSure Technologies, Incorporation since April 01, 2018. Dr. Tang has been Chief Executive Officer and Pre ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD2.10M) is about average for companies of similar size in the US market ($USD1.73M).
Compensation vs Earnings: Steve's compensation has increased by more than 20% in the past year.
Management Age and Tenure
2.3yrs
Average Tenure
58yo
Average Age
Experienced Management: OSUR's management team is considered experienced (2.3 years average tenure).
Board Age and Tenure
3.0yrs
Average Tenure
59yo
Average Age
Experienced Board: OSUR's board of directors are considered experienced (3 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 1,000 |
| Max Price | US$8.56 |
| Entity | Individual |
| Role | Chief Legal Officer Senior VP |
| Shares | 10,000 |
| Max Price | US$8.55 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Principal Accounting Officer |
| Shares | 10,000 |
| Max Price | US$9.04 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Steve Tang (58yo)
President
- Tenure: 1.6yrs
- Compensation: US$2.10m
Jack Jerrett (60yo)
Senior VP
- Tenure: 19yrs
- Compensation: US$973.46k
Roberto Cuca (51yo)
CFO & Principal Accounting Officer
- Tenure: 1.4yrs
- Compensation: US$1.05m
Brian Smith (60yo)
Vice Chairman & EVP of Innovation - DNA Genotek
- Tenure: 2.3yrs
- Compensation: US$978.65k
David Rappaport
Senior Vice President of Business Development
- Tenure: 1.6yrs
Nancy McLane
Senior Vice President of Operations
- Tenure: 0yrs
Jeanne Mell
Vice President of Corporate Communications
- Tenure: 1.3yrs
Tony Zezzo (65yo)
Executive VP & Business Unit Leader of Infectious Disease
- Tenure: 2.8yrs
- Compensation: US$1.06m
Kathy Weber (52yo)
Executive VP & Business Unit Leader of Molecular Solutions
- Tenure: 7yrs
Mike Reed (50yo)
Senior VP of R&D and Chief Science Officer
- Tenure: 3.6yrs
- Compensation: US$778.96k
Board Members
Chuck Patrick (64yo)
Independent Director
- Tenure: 13.8yrs
- Compensation: US$168.99k
Eamonn Hobbs (60yo)
Independent Director
- Tenure: 3.7yrs
- Compensation: US$157.24k
Steve Tang (58yo)
President
- Tenure: 1.6yrs
- Compensation: US$2.10m
Ronny Lancaster (67yo)
Independent Director
- Tenure: 16.5yrs
- Compensation: US$169.74k
Mike Celano (60yo)
Independent Chairman of the Board
- Tenure: 1.6yrs
- Compensation: US$506.36k
James Datin (56yo)
Director
- Tenure: 0.3yrs
Mara Aspinall (57yo)
Independent Director
- Tenure: 2.4yrs
- Compensation: US$157.24k
Aradhana Sarin (44yo)
Independent Director
- Tenure: 1.8yrs
- Compensation: US$562.31k
Company Information
OraSure Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: OraSure Technologies, Inc.
- Ticker: OSUR
- Exchange: NasdaqGS
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$485.169m
- Shares outstanding: 61.73m
- Website: https://www.orasure.com
Number of Employees
Location
- OraSure Technologies, Inc.
- 220 East First Street
- Bethlehem
- Pennsylvania
- 18015
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OSUR | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Nov 1986 |
| EP3 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 1986 |
Biography
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and inter ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/22 23:45 |
| End of Day Share Price | 2019/11/22 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.